Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Episode metadata supplied by the publisher feed · Published Nov 18, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

0:00 14:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Healthy Dialogue?

This episode is 14 minutes long.

When was this Healthy Dialogue episode published?

This episode was published on November 18, 2024.

Can I download this Healthy Dialogue episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!